<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Genet Genomic Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol Genet Genomic Med</journal-id>
<journal-id journal-id-type="doi">10.1002/(ISSN)2324-9269</journal-id>
<journal-id journal-id-type="publisher-id">MGG3</journal-id>
<journal-title-group>
<journal-title>Molecular Genetics &amp; Genomic Medicine</journal-title>
</journal-title-group>
<issn pub-type="epub">2324-9269</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30900395</article-id>
<article-id pub-id-type="pmc">6565584</article-id>
<article-id pub-id-type="doi">10.1002/mgg3.657</article-id>
<article-id pub-id-type="publisher-id">MGG3657</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Original Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Mild phenotype in Molybdenum cofactor deficiency: A new patient and review of the literature</article-title>
<alt-title alt-title-type="left-running-head">SCELSA et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" id="mgg3657-cr-0001">
<name>
<surname>Scelsa</surname>
<given-names>Barbara</given-names>
</name>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3984-0077</contrib-id>
<address>
<email>barbara.scelsa@asst-fbf-sacco.it</email>
</address>
<xref ref-type="aff" rid="mgg3657-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mgg3657-cr-0002">
<name>
<surname>Gasperini</surname>
<given-names>Serena</given-names>
</name>
<xref ref-type="aff" rid="mgg3657-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mgg3657-cr-0003">
<name>
<surname>Righini</surname>
<given-names>Andrea</given-names>
</name>
<xref ref-type="aff" rid="mgg3657-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mgg3657-cr-0004">
<name>
<surname>Iascone</surname>
<given-names>Maria</given-names>
</name>
<xref ref-type="aff" rid="mgg3657-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mgg3657-cr-0005">
<name>
<surname>Brazzoduro</surname>
<given-names>Valeria G.</given-names>
</name>
<xref ref-type="aff" rid="mgg3657-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mgg3657-cr-0006">
<name>
<surname>Veggiotti</surname>
<given-names>Pierangelo</given-names>
</name>
<xref ref-type="aff" rid="mgg3657-aff-0001">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="mgg3657-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Pediatric Neurology Unit</named-content>
<institution>V. Buzzi Children's Hospital</institution>
<named-content content-type="city">Milan</named-content>
<country country="IT">Italy</country>
</aff>
<aff id="mgg3657-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Pediatric Rare Diseases Unit, Department of Pediatrics</named-content>
<institution>MBBM Foundation, ATS Monza e Brianza</institution>
<named-content content-type="city">Monza</named-content>
<country country="IT">Italy</country>
</aff>
<aff id="mgg3657-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Pediatric Radiology and Neuroradiology</named-content>
<institution>V. Buzzi Children's Hospital</institution>
<named-content content-type="city">Milan</named-content>
<country country="IT">Italy</country>
</aff>
<aff id="mgg3657-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Laboratory of Genetic Medicine</named-content>
<institution>ASST Papa Giovanni XXIII</institution>
<named-content content-type="city">Bergamo</named-content>
<country country="IT">Italy</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break></break>
Barbara Scelsa, Pediatric Neurology Unit, V. Buzzi Children's Hospital, Milan, Italy.<break></break>
Email: <email>barbara.scelsa@asst-fbf-sacco.it</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>21</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>6</month>
<year>2019</year>
</pub-date>
<volume>7</volume>
<issue>6</issue>
<issue-id pub-id-type="doi">10.1002/mgg3.2019.7.issue-6</issue-id>
<elocation-id>e657</elocation-id>
<history>
<date date-type="received">
<day>14</day>
<month>9</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>12</day>
<month>2</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>2</month>
<year>2019</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2019 John Wiley & Sons Ltd. <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2019 The Authors. <italic>Molecular Genetics &amp; Genomic Medicine</italic> published by Wiley Periodicals, Inc.</copyright-statement>
<license license-type="creativeCommonsBy">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:MGG3-7-e657.pdf" xlink:type="simple"></self-uri>
<abstract id="mgg3657-abs-0001">
<title>Abstract</title>
<sec id="mgg3657-sec-0001">
<title>Background</title>
<p>Molybdenum cofactor deficiency (MoCD) is a rare autosomal‐recessive disorder that results in the combined deficiency of molybdenum‐dependent enzymes. Four different genes are involved in Molybdenum cofactor biosynthesis: <italic>MOCS1, MOCS2, MOCS3,</italic> and <italic>GEPH</italic>. The classical form manifests in the neonatal period with severe encephalopathy, including intractable seizures, MRI changes that resemble hypoxic‐ischemic injury, microcephaly, and early death. To date, an atypical phenotype with late‐onset has been reported in the literature in 13 patients.</p>
</sec>
<sec id="mgg3657-sec-0002">
<title>Methods</title>
<p>We describe a late‐onset and a relatively mild phenotype in a patient with <italic>MOCS2 </italic>homozygous mutation.</p>
</sec>
<sec id="mgg3657-sec-0003">
<title>Results</title>
<p>Pyramidal and extrapyramidal signs are recognized in those patients, often exacerbated by intercurrent illness. Expressive language is usually compromised. Neurological deterioration is possible even in adulthood, probably due to accumulation of sulfite with time.</p>
</sec>
<sec id="mgg3657-sec-0004">
<title>Conclusion</title>
<p>Sulfite inhibition of mitochondrial metabolism could be responsible for the ischemic lesions described in patients with MoCD or alternatively could predispose the brain to suffer an ischemic damage through the action of other insults, for instance intercurrent illness. It is possible that sulfite accumulation together with other external triggers, can lead to neurological deterioration even in adulthood. The role of other factors involved in clinical expression should be investigated to establish the reason for phenotypic variability in patients with the same mutation.</p>
</sec>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="mgg3657-kwd-0001">
<italic>MOCS2</italic>
</kwd>
<kwd id="mgg3657-kwd-0002">molybdenum cofactor</kwd>
<kwd id="mgg3657-kwd-0003">Molybdenum cofactor deficiency</kwd>
<kwd id="mgg3657-kwd-0004">neurodevelopmental outcome</kwd>
<kwd id="mgg3657-kwd-0005">sulfite oxidase</kwd>
</kwd-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="2"></table-count>
<page-count count="9"></page-count>
<word-count count="5036"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>mgg3657</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>June 2019</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.5 mode:remove_FC converted:10.07.2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="mgg3657-cit-1001" publication-type="journal">
<string-name>
<surname>Scelsa</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Gasperini</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Righini</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Iascone</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Brazzoduro</surname>
<given-names>VG</given-names>
</string-name>, <string-name>
<surname>Veggiotti</surname>
<given-names>P</given-names>
</string-name>. <article-title>Mild phenotype in Molybdenum cofactor deficiency: A new patient and review of the literature</article-title>. <source xml:lang="en"/>Mol Genet Genomic Med. <year>2019</year>;<volume>7</volume>:<elocation-id>e657</elocation-id>
<pub-id pub-id-type="doi">10.1002/mgg3.657</pub-id>
<pub-id pub-id-type="pmid">30900395</pub-id></mixed-citation>
</p>
</notes>
</front>
<body>
<sec id="mgg3657-sec-0005">
<label>1</label>
<title>INTRODUCTION</title>
<p>Molybdenum cofactor deficiency (MoCD) is a rare autosomal‐recessive disorder that results in the combined deficiency of molybdenum‐dependent enzymes, including xanthine oxidase, sulfite oxidase, and aldehyde oxidase (Johnson et al., <xref ref-type="ref" rid="mgg3657-bib-0007">2001</xref>). Four different genes are involved in Molybdenum cofactor biosynthesis: <italic>MOCS1</italic> (OMIM*603707), <italic>MOCS2</italic> (OMIM*603708), <italic>MOCS3</italic> (OMIM*609277), and <italic>GEPH</italic> (OMIM*603930) (Leimkühler, Freuer, Araujo, Rajagopalan, &amp; Mendel, <xref ref-type="ref" rid="mgg3657-bib-0010">2003</xref>). <italic>MOCS1</italic> mutations are responsible for more than half of the patients, followed by <italic>MOCS2</italic> (Mechler, Mountford, Hoffmann, &amp; Ries, <xref ref-type="ref" rid="mgg3657-bib-0013">2015</xref>). <italic>GEPH</italic>mutations have been described in two families, respectively, of Danish and of Algerian origin (Reiss et al., <xref ref-type="ref" rid="mgg3657-bib-0017">2001</xref>,<xref ref-type="ref" rid="mgg3657-bib-0018">2011</xref>). Only one patient has been reported so far with <italic>MOCS3</italic> gene mutation (Huijmans et al., <xref ref-type="ref" rid="mgg3657-bib-0006">2017</xref>).</p>
<p>The classical form manifests in the neonatal period with severe encephalopathy, including intractable seizures, MRI changes that resemble hypoxic‐ischemic injury, microcephaly, and early death (Mechler et al., <xref ref-type="ref" rid="mgg3657-bib-0013">2015</xref>). In the literature, an atypical phenotype with late‐onset has been recognized and to date only 13 patients are reported (Alkufri et al., <xref ref-type="ref" rid="mgg3657-bib-0001">2013</xref>; Arenas et al., <xref ref-type="ref" rid="mgg3657-bib-0003">2009</xref>; Graf, Oleinik, Jack, Weiss, &amp; Johnson, <xref ref-type="ref" rid="mgg3657-bib-0004">1998</xref>; Hughes, Fairbanks, Simmonds, &amp; Robinson, <xref ref-type="ref" rid="mgg3657-bib-0005">1998</xref>; Huijmans et al., <xref ref-type="ref" rid="mgg3657-bib-0006">2017</xref>; Johnson et al., <xref ref-type="ref" rid="mgg3657-bib-0007">2001</xref>; Johnson, Wuebbens, Mandell, &amp; Shih, <xref ref-type="ref" rid="mgg3657-bib-0008">1988</xref>; Mayr et al., <xref ref-type="ref" rid="mgg3657-bib-0012">2018</xref>; Megahed et al., <xref ref-type="ref" rid="mgg3657-bib-0014">2016</xref>; Mize, Johnson, &amp; Rajagopalan, <xref ref-type="ref" rid="mgg3657-bib-0015">1995</xref>; Shih et al., <xref ref-type="ref" rid="mgg3657-bib-0019">1977</xref>; Vijayakumar et al., <xref ref-type="ref" rid="mgg3657-bib-0020">2011</xref>; Zaki et al., <xref ref-type="ref" rid="mgg3657-bib-0021">2016</xref>).</p>
<p>In late‐onset MoCD patients, the onset is within the first 2 years of life. Usually the clinical manifestations include developmental delay, lens dislocation, extrapyramidal, and pyramidal symptoms often arising abruptly after an intercurrent illness. Seizures are less common comparing to the classical form (Zaki et al., <xref ref-type="ref" rid="mgg3657-bib-0021">2016</xref>). The clinical course is variable including patients with predominant extrapyramidal signs, occurring even in adulthood, and patients with catastrophic neurological deterioration. Basal ganglia and dentate nuclei changes are often recognized as an isolated finding in MRI of patients with late‐onset and mild clinical course. On the other hand, MRI changes of patients with late‐onset and severe clinical course are similar to the early‐onset form of MoCD (diffuse brain atrophy, gliosis, arrested development of myelination, and cystic necrosis of cerebral white matter).</p>
<p>We describe a late‐onset and a relatively mild phenotype in a patient with <italic>MOCS2 </italic>homozygous mutation.</p>
<sec id="mgg3657-sec-0006">
<label>1.1</label>
<title>Ethical compliance</title>
<p>Informed consent for patient information to be published was provided by the parents of the child.</p>
</sec>
<sec id="mgg3657-sec-0007">
<label>1.2</label>
<title>Case report</title>
<p>Our patient is the second child born to unrelated parents of Chinese origin. There is no family history of neurological or metabolic disorders in the family. She was born at term after an uneventful pregnancy and delivery. Her psychomotor development in the first 15 months of life was described as normal. The first symptoms of the disease were recognized after a febrile illness at age 16 months. She developed left side hemiparesis and was admitted to a hospital in China. Brain MRI performed in China was not available. The family had with them only a translation of the clinical report. Abnormal signal intensity was reported in the dentate nuclei and in the globus pallidi, predominantly in the right side (consistent with the side of the hemiparesis). The child returned to Italy after 4 weeks and was admitted to a local hospital. A second MRI was performed and a cystic cavitation of the globus pallidus was detected in the right side. She underwent a thrombophilic screening including protein C activity, protein S activity, antithrombin, lupus anticoagulant, lipoprotein A, homocysteine, PT, PTT, and antiphospholipid antibodies. A vascular stroke was suspected on the basis of the MRI and the increased level of lipoprotein A. She was given acetylsalicylic acid 50 mg per day to prevent further vascular strokes.</p>
<p>The child came to our attention for the first time at 20 months. At admittance she was found to have a mild left hemiparesis, not impairing her ability to walk. She had normal behavior and social skills. She did not show any dysmorphic features and her head circumference was normal for age. She had an isolated myofibroma in her left wrist. Several investigations were carried out including coagulation profile, plasma and urinary amino acid, urinary organic acid, brain MRI, and EEG. MRI revealed areas of altered signal in the dentate nucleus and globus pallidus, bilaterally, with cystic cavitation on the right side (Figure <xref ref-type="fig" rid="mgg3657-fig-0001">1</xref>a,b). EEG showed a sharp delta activity increased by sleep over the right parieto‐temporal area. Lipoprotein A was normal as well as the coagulation profile. Sulfite test was positive, S‐Sulfocysteine was found in urine, and plasma uric acid was low (Table <xref ref-type="table" rid="mgg3657-tbl-0001">1</xref>). Initial genetic investigations by array‐CGH gave normal results. She was suspected to have a disorder of sulfur amino acids and sent to a referring center for metabolic disorders. Acetylsalicylic acid was discontinued. The child was submitted to further genetic investigation by trio‐based whole exome sequencing analysis. The patient is homozygous for a single base substitution of valine in place of phenylalanine (p.Val7Phe, NM_176806.3:c.19G&gt;T) in <italic>MOCS2</italic> gene while both parents resulted heterozygous carriers. The variant was confirmed by Sanger sequencing in child and both parents.</p>
<fig fig-type="Figure" id="mgg3657-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>(a, b) T2‐FLAIR axial sections showing in the pallidus regions low signal intensity (cystic cavitation) in the right side and high signal intensity in the left side (black arrows); abnormal hyperintense signal in the dentate nuclei (white arrows) at 20 months. (c, d) corresponding sections, study confirming previous findings at 38 months. (e, f) T2‐FLAIR axial sections showing the same lesion of previous studies (white arrows), with an additional focal hyperintense lesion within the posterior striatum on right side at 3 years and 11 months (arrowhead)</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="MGG3-7-e657-g001"></graphic>
</fig>
<table-wrap id="mgg3657-tbl-0001" orientation="portrait" position="float" xml:lang="en">
<label>Table 1</label>
<caption>
<p>Biochemical profile of the patient</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="2" valign="top"> </th>
<th align="left" colspan="3" rowspan="1" style="border-bottom:solid 1px #000000" valign="top">Age</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">24 months</th>
<th align="left" colspan="1" rowspan="1" valign="top">38 months</th>
<th align="left" colspan="1" rowspan="1" valign="top">5 years</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Sulfite test</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+/−</td>
<td align="left" colspan="1" rowspan="1">+/−</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">S‐Sulfocystine (U)</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">↑</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Taurine (U)</td>
<td align="left" colspan="1" rowspan="1">3,292 µmol/L (630–1580)</td>
<td align="left" colspan="1" rowspan="1">1676 µmol/L (630–1580)</td>
<td align="left" colspan="1" rowspan="1">304 µmol/L (17–230)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cystine (P)</td>
<td align="left" colspan="1" rowspan="1">12 µmol/L (37–77)</td>
<td align="left" colspan="1" rowspan="1">5 µmol/L (37–77)</td>
<td align="left" colspan="1" rowspan="1">11 µmol/L (37–77)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cystine (U)</td>
<td align="left" colspan="1" rowspan="1">9 µmol/L (15–35)</td>
<td align="left" colspan="1" rowspan="1">2 µmol/L (15–35)</td>
<td align="left" colspan="1" rowspan="1">1 µmol/L (4–11)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Uric acid (P)</td>
<td align="left" colspan="1" rowspan="1">1.8 mg/dl (2.4–5.7)</td>
<td align="left" colspan="1" rowspan="1">0.2 mg/dl (2.4–5.7)</td>
<td align="left" colspan="1" rowspan="1">0.8 (2.4–5.7)</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>At 21 months, she had her first and only focal seizure. The EEG confirmed the previous findings. No additional seizures were reported in the following months.</p>
<p>At 2 years of age the Griffiths Scale developmental quotient was 81 (low‐average range).</p>
<p>At 3 years of age she was submitted to a routine control including brain MRI. Clinically, she could walk outdoor independently, even though she had left side hemiparesis predominant in the inferior limb. The patient was found to have expressive language delay, although her understanding was adequate for age.</p>
<p>At 3 years and 2 months of age, after an intercurrent illness, she was admitted to our hospital for the sudden onset of extrapyramidal signs. The child displayed facial grimaces and choreic movements of the limbs. Since the onset of new neurological signs, she was submitted to MRI that confirmed the previous findings (Figure <xref ref-type="fig" rid="mgg3657-fig-0001">1</xref>c,d). Coagulation profile, including PT, PTT, D‐dimer, was in the normal range, except for a slight elevation of fibrinogen (451 mg/dl‐reference values 150–400). The child was started again with acetylsalicylic acid 50 mg per day. The extrapyramidal movements elapsed in a few days.</p>
<p>At 3 years and 11 months, an additional lesion was found in the posterior part of the right striatum (Figure <xref ref-type="fig" rid="mgg3657-fig-0001">1</xref>e,f) on brain MRI performed as a routine control. It is likely that the extrapyramidal signs described above were secondary to this additional lesion, not detected in the previous MRI (Figure <xref ref-type="fig" rid="mgg3657-fig-0001">1</xref>c,d). The last MRI was performed at age 6 years and no variations were found.</p>
<p>Ophthalmological evaluations were carried out every year with normal results, except for a mild hypermetropia (OO+2). Lens dislocation has not been detected yet.</p>
<p>At 4 years of age, the Griffiths scales developmental quotient was 88 (low‐average range).</p>
<p>Our patient is currently 6 years and 11 month old. She is seizure‐free and has left side hemiparesis predominant in the lower limb, not impairing her ability to walk. She is not following a specific diet, although she is still taking acetylsalicylic acid. She is attending mainstream school with support for language impairment.</p>
<p>At age 6 years and 11 months, the scores obtained with a nonverbal intelligence test (C‐TONI/ Comprehensive Test of Non Verbal Intelligence) were above average (IQ 114).</p>
</sec>
</sec>
<sec id="mgg3657-sec-0008">
<label>2</label>
<title>DISCUSSION</title>
<p>Two forms of MoCD are currently recognized. In the classical severe form of MoCD, the onset is in the first month of life with intractable seizures, feeding difficulties, quadriplegia, and early death (Johnson et al., <xref ref-type="ref" rid="mgg3657-bib-0007">2001</xref>). Dysmorphic features are also described in most children with the classical form: frontal bossing, full cheeks, widely spaced eyes, elongated palpebral fissures, thick lips, and long philtrum (Parini et al., <xref ref-type="ref" rid="mgg3657-bib-0016">1997</xref>). Lens dislocation is often reported but only in children surviving the neonatal period (Mechler et al., <xref ref-type="ref" rid="mgg3657-bib-0013">2015</xref>).</p>
<p>A late‐onset form has also been reported in literature in 13 patients (Alkufri et al., <xref ref-type="ref" rid="mgg3657-bib-0001">2013</xref>; Arenas et al., <xref ref-type="ref" rid="mgg3657-bib-0003">2009</xref>; Graf et al., <xref ref-type="ref" rid="mgg3657-bib-0004">1998</xref>; Hughes et al., <xref ref-type="ref" rid="mgg3657-bib-0005">1998</xref>; Huijmans et al., <xref ref-type="ref" rid="mgg3657-bib-0006">2017</xref>; Johnson et al., <xref ref-type="ref" rid="mgg3657-bib-0007">2001</xref>, <xref ref-type="ref" rid="mgg3657-bib-0008">1988</xref>; Mayr et al., <xref ref-type="ref" rid="mgg3657-bib-0012">2018</xref>; Megahed et al., <xref ref-type="ref" rid="mgg3657-bib-0014">2016</xref>; Mize et al., <xref ref-type="ref" rid="mgg3657-bib-0015">1995</xref>; Shih et al., <xref ref-type="ref" rid="mgg3657-bib-0019">1977</xref>; Vijayakumar et al., <xref ref-type="ref" rid="mgg3657-bib-0020">2011</xref>; Zaki et al., <xref ref-type="ref" rid="mgg3657-bib-0021">2016</xref>). Table <xref ref-type="table" rid="mgg3657-tbl-0002">2</xref> below compares the clinical, genetic, neurological, and neuroradiological findings of those with our patient. The clinical course of late‐onset MoCD includes patients with neurological severe deterioration and patients with milder manifestations. When the disease begins in the first year of life, the outcome is usually severe with deterioration of motor and intellectual skills, very similar to those surviving the classical form of MoCD. When the disease begins after the first year of life, patients have predominantly extrapyramidal and focal pyramidal signs often occurring and/or worsening in the contest of intercurrent illness (Table <xref ref-type="table" rid="mgg3657-tbl-0002">2</xref>). Marfanoid habitus and mild dysmorphic features are described in few patients (Huijmans et al., <xref ref-type="ref" rid="mgg3657-bib-0006">2017</xref>; Mayr et al., <xref ref-type="ref" rid="mgg3657-bib-0012">2018</xref>; Mize et al., <xref ref-type="ref" rid="mgg3657-bib-0015">1995</xref>; Zaki et al., <xref ref-type="ref" rid="mgg3657-bib-0021">2016</xref>). Lens dislocation is generally detected after 4–5 years of age. Hughes and Alkufri describe a child who presented only lens dislocation in infancy. She developed parkinsonism and dystonia after age 23 years (Hughes et al., <xref ref-type="ref" rid="mgg3657-bib-0005">1998</xref> and Alkufri et al., <xref ref-type="ref" rid="mgg3657-bib-0001">2013</xref>). All patients have some degree of language delay especially in the expressive ability. In most studies, cognitive functions are not described with formal tests, but mild intellectual disability is reported in the majority of patients. Seizures are not very frequent and controlled by antiepileptic medications. Our patient is very similar to those with mild clinical course reported in the literature (Arenas et al., <xref ref-type="ref" rid="mgg3657-bib-0003">2009</xref>; Huijmans et al., <xref ref-type="ref" rid="mgg3657-bib-0006">2017</xref>; Johnson et al., <xref ref-type="ref" rid="mgg3657-bib-0007">2001</xref>,<xref ref-type="ref" rid="mgg3657-bib-0008">1988</xref>; Mayr et al., <xref ref-type="ref" rid="mgg3657-bib-0012">2018</xref>; Mize et al., <xref ref-type="ref" rid="mgg3657-bib-0015">1995</xref>; Shih et al., <xref ref-type="ref" rid="mgg3657-bib-0019">1977</xref>; Vijayakumar case 2 et al., <xref ref-type="ref" rid="mgg3657-bib-0020">2011</xref>). She was presented with pyramidal signs in the second year of life after a viral illness. Transient extrapyramidal signs were detected at 3 years of age after an intercurrent infection. The clinical course in our patient seems to be mild, but the child is currently only 6 years old.</p>
<table-wrap id="mgg3657-tbl-0002" orientation="portrait" position="float" xml:lang="en">
<label>Table 2</label>
<caption>
<p>Review of patients described in the literature with mild phenotype of MoCD</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="2" valign="top"> </th>
<th align="left" colspan="1" rowspan="2" valign="top">Shih et al. (<xref ref-type="ref" rid="mgg3657-bib-0019">1977</xref>)‐Johnson et al. (<xref ref-type="ref" rid="mgg3657-bib-0008">1988</xref>)</th>
<th align="left" colspan="1" rowspan="2" valign="top">Mize et al. (<xref ref-type="ref" rid="mgg3657-bib-0015">1995</xref>)</th>
<th align="left" colspan="1" rowspan="2" valign="top">Graf et al. (<xref ref-type="ref" rid="mgg3657-bib-0004">1998</xref>)</th>
<th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="top">Hughes et al. (<xref ref-type="ref" rid="mgg3657-bib-0005">1998</xref>) and Alkufri et al. (<xref ref-type="ref" rid="mgg3657-bib-0001">2013</xref>)</th>
<th align="left" colspan="1" rowspan="2" valign="top">Johnson et al. (<xref ref-type="ref" rid="mgg3657-bib-0007">2001</xref>)</th>
<th align="left" colspan="1" rowspan="2" valign="top">Arenas et al. (<xref ref-type="ref" rid="mgg3657-bib-0003">2009</xref>)</th>
<th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="top">Vijayakumar et al. (<xref ref-type="ref" rid="mgg3657-bib-0020">2011</xref>)</th>
<th align="left" colspan="1" rowspan="2" valign="top">Zaki et al. (<xref ref-type="ref" rid="mgg3657-bib-0021">2016</xref>)</th>
<th align="left" colspan="1" rowspan="2" valign="top">Megahed et al. (<xref ref-type="ref" rid="mgg3657-bib-0014">2016</xref>)</th>
<th align="left" colspan="1" rowspan="2" valign="top">Huijmans et al. (<xref ref-type="ref" rid="mgg3657-bib-0006">2017</xref>)</th>
<th align="left" colspan="1" rowspan="2" valign="top">Mayr et al. (<xref ref-type="ref" rid="mgg3657-bib-0012">2018</xref>)</th>
<th align="left" colspan="1" rowspan="2" valign="top">Current study 2019</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Case 1</th>
<th align="left" colspan="1" rowspan="1" valign="top">Case 2 (sister)</th>
<th align="left" colspan="1" rowspan="1" valign="top">Case 1</th>
<th align="left" colspan="1" rowspan="1" valign="top">Case 2</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Age at onset (months)</td>
<td align="left" colspan="1" rowspan="1">17</td>
<td align="left" colspan="1" rowspan="1">24</td>
<td align="left" colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">12</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">15</td>
<td align="left" colspan="1" rowspan="1">24</td>
<td align="left" colspan="1" rowspan="1">8</td>
<td align="left" colspan="1" rowspan="1">24</td>
<td align="left" colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">14</td>
<td align="left" colspan="1" rowspan="1">7</td>
<td align="left" colspan="1" rowspan="1">16</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Dysmorphic features</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">Yes (marfanoid habitus)</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">macrocephaly</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">Yes (frontal bossing, depressed nasal bridge, anteverted nares, retrognathia, long philtrum, and low set ears.)</td>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1">Yes (marfanoid habitus)</td>
<td align="left" colspan="1" rowspan="1">Yes (marfanoid habitus)</td>
<td align="left" colspan="1" rowspan="1">no</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Psychomotor development</td>
<td align="left" colspan="1" rowspan="1">delay</td>
<td align="left" colspan="1" rowspan="1">delay</td>
<td align="left" colspan="1" rowspan="1">delay</td>
<td align="left" colspan="1" rowspan="1">delay</td>
<td align="left" colspan="1" rowspan="1">Normal, deterioration at 23 years of age</td>
<td align="left" colspan="1" rowspan="1">Delay</td>
<td align="left" colspan="1" rowspan="1">delay</td>
<td align="left" colspan="1" rowspan="1">delay</td>
<td align="left" colspan="1" rowspan="1">delay</td>
<td align="left" colspan="1" rowspan="1">delay</td>
<td align="left" colspan="1" rowspan="1">delay</td>
<td align="left" colspan="1" rowspan="1">Delay (IQ 50)</td>
<td align="left" colspan="1" rowspan="1">Delay</td>
<td align="left" colspan="1" rowspan="1">delay</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Behavioral disorders</td>
<td align="left" colspan="1" rowspan="1">yes (intermittent)</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">Yes(irritability)</td>
<td align="left" colspan="1" rowspan="1">yes (in infancy mild attention deficit, in adulthood apathy)</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">yes (hyperkinesia)</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">yes (autistic features)</td>
<td align="left" colspan="1" rowspan="1">yes (autistic features)</td>
<td align="left" colspan="1" rowspan="1">no</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Extrapyramidal signs</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">Yes (coordination deficit)</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">Yes (at 23 years of age)</td>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">Yes (intermittent)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ophthalmological findings (age‐years)</td>
<td align="left" colspan="1" rowspan="1">Lens dislocation (4)</td>
<td align="left" colspan="1" rowspan="1">Lens dislocation (8)</td>
<td align="left" colspan="1" rowspan="1">Lens dislocation (2)</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">Lens dislocation (6)</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">Lens dislocation ‐myopia(4)</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">Lens dislocation (5)</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">strabismus</td>
<td align="left" colspan="1" rowspan="1">Hyperopia</td>
<td align="left" colspan="1" rowspan="1">no</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Worsening with intercurrent illness</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">neuromotor and intellectual deterioration</td>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">Yes in adulthood</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">no</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">seizures</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">Yes (one)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pyramidal signs</td>
<td align="left" colspan="1" rowspan="1">yes (hemiplegia)</td>
<td align="left" colspan="1" rowspan="1">yes (hemiplegia)</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">Yes (hemiplegia)</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Independent walking</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">Unstable gait after 23 years of age</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">Yes (unstable)</td>
<td align="left" colspan="1" rowspan="1">yes (unstable)</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Feeding difficulties</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">Yes after 23 years of age</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">no</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Language development</td>
<td align="left" colspan="1" rowspan="1">episode of aphasia</td>
<td align="left" colspan="1" rowspan="1">Delay</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">Regression after 17 months‐absent at last examination</td>
<td align="left" colspan="1" rowspan="1">Normal‐ regression after 23 years of age (severe dysphonia‐anarthria)</td>
<td align="left" colspan="1" rowspan="1">Delay (expressive language)</td>
<td align="left" colspan="1" rowspan="1">Delay (expressive and receptive language)</td>
<td align="left" colspan="1" rowspan="1">delay</td>
<td align="left" colspan="1" rowspan="1">Delay (verbal dyspraxia)</td>
<td align="left" colspan="1" rowspan="1">delay</td>
<td align="left" colspan="1" rowspan="1">Delay</td>
<td align="left" colspan="1" rowspan="1">Delay (expressive language)</td>
<td align="left" colspan="1" rowspan="1">Delay (expressive language)</td>
<td align="left" colspan="1" rowspan="1">Delay (expressive language)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Outcome at last examination (age‐y)</td>
<td align="left" colspan="1" rowspan="1">Mild‐moderate (4)</td>
<td align="left" colspan="1" rowspan="1">Moderate (22)</td>
<td align="left" colspan="1" rowspan="1">Severe (2)</td>
<td align="left" colspan="1" rowspan="1">Severe (3)</td>
<td align="left" colspan="1" rowspan="1">Severe (23)</td>
<td align="left" colspan="1" rowspan="1">Mild (4.5)</td>
<td align="left" colspan="1" rowspan="1">Mild (7)</td>
<td align="left" colspan="1" rowspan="1">Severe (4)</td>
<td align="left" colspan="1" rowspan="1">Mild‐Moderate (7)</td>
<td align="left" colspan="1" rowspan="1">Severe (death at 5.5 years)</td>
<td align="left" colspan="1" rowspan="1">Moderate (6)</td>
<td align="left" colspan="1" rowspan="1">Moderate (17)</td>
<td align="left" colspan="1" rowspan="1">Mild (14)</td>
<td align="left" colspan="1" rowspan="1">Mild (6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Uric acid (plasma)</td>
<td align="left" colspan="1" rowspan="1">Normal</td>
<td align="left" colspan="1" rowspan="1">↓</td>
<td align="left" colspan="1" rowspan="1">↓</td>
<td align="left" colspan="1" rowspan="1">↓</td>
<td align="left" colspan="1" rowspan="1">↓</td>
<td align="left" colspan="1" rowspan="1">normal</td>
<td align="left" colspan="1" rowspan="1">normal</td>
<td align="left" colspan="1" rowspan="1">↓</td>
<td align="left" colspan="1" rowspan="1">normal</td>
<td align="left" colspan="1" rowspan="1">normal</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">
<italic>N</italic>‐↓</td>
<td align="left" colspan="1" rowspan="1">↓</td>
<td align="left" colspan="1" rowspan="1">↓</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">S‐sulfocysteine</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">↑</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Sulfi test</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">NP</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">NP</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">‐</td>
<td align="left" colspan="1" rowspan="1">+</td>
<td align="left" colspan="1" rowspan="1">+</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MRI</td>
<td align="left" colspan="1" rowspan="1">NP</td>
<td align="left" colspan="1" rowspan="1">LN</td>
<td align="left" colspan="1" rowspan="1">BG‐SWM</td>
<td align="left" colspan="1" rowspan="1">BG‐DN</td>
<td align="left" colspan="1" rowspan="1">BG</td>
<td align="left" colspan="1" rowspan="1">BG‐cortical dysplasia</td>
<td align="left" colspan="1" rowspan="1">DN‐parietal cleft</td>
<td align="left" colspan="1" rowspan="1">LN‐A</td>
<td align="left" colspan="1" rowspan="1">DN</td>
<td align="left" colspan="1" rowspan="1">BG‐SWM‐A</td>
<td align="left" colspan="1" rowspan="1">A</td>
<td align="left" colspan="1" rowspan="1">SWM</td>
<td align="left" colspan="1" rowspan="1">BG‐SWM</td>
<td align="left" colspan="1" rowspan="1">BG‐DN‐LN</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">treatment</td>
<td align="left" colspan="1" rowspan="1">Antiepileptic drugs</td>
<td align="left" colspan="1" rowspan="1">none</td>
<td align="left" colspan="1" rowspan="1">Antiepileptic drugs</td>
<td align="left" colspan="1" rowspan="1">Antiepileptic drugs</td>
<td align="left" colspan="1" rowspan="1">Levodopa prednisolone</td>
<td align="left" colspan="1" rowspan="1">none</td>
<td align="left" colspan="1" rowspan="1">no</td>
<td align="left" colspan="1" rowspan="1">Antiepileptic drugs</td>
<td align="left" colspan="1" rowspan="1">none</td>
<td align="left" colspan="1" rowspan="1">Antiepileptic drugs</td>
<td align="left" colspan="1" rowspan="1">Antiepileptic drugs, Omega3, B‐vitamins</td>
<td align="left" colspan="1" rowspan="1">Low‐methionine diet</td>
<td align="left" colspan="1" rowspan="1">Low‐methionine diet</td>
<td align="left" colspan="1" rowspan="1">Acetylsalicylic acid</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Molecular analysis<xref ref-type="fn" rid="mgg3657-note-0002">a</xref>
</td>
<td align="left" colspan="1" rowspan="1">NP</td>
<td align="left" colspan="1" rowspan="1">NP</td>
<td align="left" colspan="1" rowspan="1">NP</td>
<td align="left" colspan="1" rowspan="1">
<italic>MOCS2 </italic> heterozygous variants: NM_004531.4:c.377+1G&gt;C; and NM_004531.4:c.539_540del, p.Lys180fs</td>
<td align="left" colspan="1" rowspan="1">
<italic>MOCS2 </italic>heterozygous variants: NM_004531.4:c.377+1G&gt;C; and NM_004531.4:c.539_540del; p.Lys180fs</td>
<td align="left" colspan="1" rowspan="1">
<italic>MOCS2</italic>‐heterozygous variants: NM_176806.3:c.16C&gt;T; p.Gln6ter and 19G&gt;T and NM_176806.3:c.19G&gt;T; p.Val7Phe</td>
<td align="left" colspan="1" rowspan="1">
<italic>MOCS1</italic>‐homozygous variant: NM_001075098.3:c.<xref ref-type="fn" rid="mgg3657-note-0002">a</xref>7+6T&gt;C</td>
<td align="left" colspan="1" rowspan="1">
<italic>MOCS1</italic>C&gt;t (Arg91 Trp)</td>
<td align="left" colspan="1" rowspan="1">
<italic>MOCS1</italic>‐homozygous variant: NM_001075098.3:c.<xref ref-type="fn" rid="mgg3657-note-0002">a</xref>7+6T&gt;C</td>
<td align="left" colspan="1" rowspan="1">
<italic>MOCS2 </italic>homozygous variant: NM_176806.3: c.3G&gt;A p.Met1?</td>
<td align="left" colspan="1" rowspan="1">
<italic>MOCS2 </italic>homozygous variant NM_176806.3: c.3G&gt;A p.Met1?</td>
<td align="left" colspan="1" rowspan="1">
<italic>MOCS3 </italic>homozygous variant: NM_014484.4:c.769G&gt;A, p.Ala257Thr</td>
<td align="left" colspan="1" rowspan="1">
<italic>MOCS1 </italic>Homozygous c.1338delG</td>
<td align="left" colspan="1" rowspan="1">
<italic>MOCS2</italic>‐ homozygous variant: NM_176806.3:c.19G&gt;T; p.Val7Phe</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<title>Note</title>
<fn id="mgg3657-note-0001">
<p>NA: not available; NP: not performed; N: normal; IQ: intelligence quotient; BG: basal ganglia lesions; DN: dentate nuclei lesions; LN: lentiform nuclei lesions; SWM: abnormality of subcortical white matter‐A: atrophy.</p>
</fn>
<fn id="mgg3657-note-0002">
<label>a</label>
<p>Following HGVS nomenclature.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>There is not clear genotype‐phenotype correlation in late‐onset MoCD. As it is shown in Table <xref ref-type="table" rid="mgg3657-tbl-0002">2</xref>, <italic>MOCS2</italic> and <italic>MOCS1</italic> mutations are described in the majority of patients. <italic>MOCS3</italic>mutation was found in only one patient (Huijmans et al., <xref ref-type="ref" rid="mgg3657-bib-0006">2017</xref>). Our patient displays the same V7F substitution described in the patient reported by Johnson, but in both alleles (Johnson et al., <xref ref-type="ref" rid="mgg3657-bib-0007">2001</xref>). The mild phenotype of this child was attributable to the residual activity of the V7F allele (Johnson et al., <xref ref-type="ref" rid="mgg3657-bib-0007">2001</xref>; Leimkuhler et al., <xref ref-type="ref" rid="mgg3657-bib-0010">2003</xref>). It is possible that a residual activity of molybdenum cofactor enzymes is responsible for late‐onset and milder phenotypes in MoCD (Mayr et al., <xref ref-type="ref" rid="mgg3657-bib-0012">2018</xref>). However, this is true only in part in fact the same mutation in the same family can be responsible for different clinical courses (Alkufri et al., <xref ref-type="ref" rid="mgg3657-bib-0001">2013</xref>; Hughes et al., <xref ref-type="ref" rid="mgg3657-bib-0005">1998</xref>; Vijayakumar et al., <xref ref-type="ref" rid="mgg3657-bib-0020">2011</xref>). The phenotype is probably a spectrum of manifestations starting from neonatal period to adulthood. Even though the role of other factors involved in clinical expression is still unclear, intercurrent illness seems to act as a trigger of neurological manifestations.</p>
<p>The diagnosis is usually established through biochemical parameters. However, the biochemical findings can be misleading and elevated urinary excretion of S‐sulfocysteine seems to be a more constant finding. Some patients might have false negative sulfite test and normal plasma uric acid (Reiss et al., <xref ref-type="ref" rid="mgg3657-bib-0018">2011</xref>). For that reason, the diagnosis can be missed especially in late‐presenters with mild symptoms.</p>
<p>Brain MRI can show some peculiar aspects resembling, in the most severe patients, hypoxic‐ischemic encephalopathy (Appignani, Kaye, &amp; Wolpert, <xref ref-type="ref" rid="mgg3657-bib-0002">1996</xref>). MRI changes include brain atrophy, polymicrogyria, pontocerebellar hypoplasia, and cystic necrosis of cerebral white matter (Vijayakumar et al., <xref ref-type="ref" rid="mgg3657-bib-0020">2011</xref>). Basal ganglia and dentate nuclei changes are often recognized as an isolated finding in late‐presenters with mild clinical course, including our patient (Vijayakumar et al., <xref ref-type="ref" rid="mgg3657-bib-0020">2011</xref>).</p>
<p>The mechanism of brain damage is likely related to sulfite toxicity (Zhang, Vincent, Halliwell, &amp; Wong, <xref ref-type="ref" rid="mgg3657-bib-0022">2004</xref>). As already stated, neuroradiological findings can mimic hypoxic‐ischemic encephalopathy (Appignani et al., <xref ref-type="ref" rid="mgg3657-bib-0002">1996</xref>). In fact, both conditions share similar pathogenic mechanism of insult, even though the etiology is striking different. In MoCD, it is the sulfite accumulation that inhibits mitochondrial metabolism, in particular glutamate dehydrogenase. Glutamate toxicity could be responsible for the ischemic lesions described or alternatively could predispose the brain to suffer an ischemic damage through the action of other insults, for instance intercurrent illness (Zhang et al., <xref ref-type="ref" rid="mgg3657-bib-0022">2004</xref>). It is likely that continuous sulfite accumulation on the basal ganglia is responsible for the neurological deterioration (Alkufri et al., <xref ref-type="ref" rid="mgg3657-bib-0001">2013</xref>). Nevertheless, the activation of the inflammatory cascade could also be responsible for additional brain damage and exacerbation of neurological symptoms. Our patient showed a slight elevation of fibrinogen in the contest of disease exacerbation. This elevation might be interpreted as an indirect sign of inflammatory cascade activation. In our patient, resolution of extrapyramidal signs occurred after acetylsalicylate was reintroduced. However, the role of salicylate is uncertain in stabilizing this condition and cannot be recommended. Even though the evidence for this secondary mechanism of injury has not been established, this observation may lead to additional treatment options especially for late MoCD presenters. However, the administration of steroid in the patient described by Alkufri gave limited improvement of parkinsonism and dystonia (Alkufri et al., <xref ref-type="ref" rid="mgg3657-bib-0001">2013</xref>). With this regard, Kumar suggested that NMDA‐R antagonists, calcium influx, and calpain activity blockers could prevent neurotoxicity in a MoCD murine model (Kumar et al., <xref ref-type="ref" rid="mgg3657-bib-0009">2017</xref>).</p>
<p>In the attempt to reduce sulfite accumulation, several treatments have been suggested with limited benefit. Cyclic pyranopterin monophosphate (cPMP) is the only effective treatment for <italic>MOCS1</italic> patients, even though cannot reverse brain injuries already established before treatment (Lubout et al., <xref ref-type="ref" rid="mgg3657-bib-0011">2018</xref>).</p>
<p>No treatment is currently available for patients with <italic>MOCS2</italic> mutations, but pyridoxine supplementation seems to relieve some of the symptoms.</p>
</sec>
<sec id="mgg3657-sec-0009">
<label>3</label>
<title>CONCLUSION</title>
<p>In patients with mild unexplained neurological symptoms, we suggest to consider MoCD as differential diagnosis by performing uric acid, sulfitest, and urinary amino acids. Patients with mild MoCD should be followed up until adult life. It is possible that sulfite accumulates with time and together with other external triggers, can lead to neurological deterioration even in adulthood. The role of other factors involved in clinical expression should be investigated to establish the reason for phenotypic variability in patients with the same mutation. The evidence that ischemic damage could also be induced by inflammatory stimuli would open the way to neuroprotection treatments with possible improvement of the outcome, at least in some patients.</p>
</sec>
<sec id="mgg3657-sec-0010" sec-type="COI-statement">
<title>CONFLICT OF INTEREST</title>
<p>The Authors declare that there is no conflict of interest.</p>
</sec>
</body>
<back>
<ack id="mgg3657-sec-0011">
<title>ACKNOWLEDGMENTS</title>
<p>The authors thank Dr Carlo Corbetta and his collaborators at the V. Buzzi Children's Hospital‐Metabolic Disorder Laboratory for carrying out the biochemical investigation of this patient.</p>
</ack>
<ref-list content-type="cited-references" id="mgg3657-bibl-0001">
<title>REFERENCES</title>
<ref id="mgg3657-bib-0001">
<mixed-citation id="mgg3657-cit-0001" publication-type="journal">
<string-name>
<surname>Alkufri</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Harrower</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Rahman</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Hughes</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Mundy</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Knibb</surname>, <given-names>J. A.</given-names>
</string-name>, … <string-name>
<surname>Samuel</surname>, <given-names>M.</given-names>
</string-name> (<year>2013</year>). <article-title>Molybdenum cofactor deficiency presenting with a parkinsonism‐dystonia syndrome</article-title>. <source xml:lang="en"/>Movement Disorders, <volume>28</volume>, <fpage>399</fpage>–<lpage>401</lpage>. <pub-id pub-id-type="doi">10.1002/mds.25276</pub-id>
<pub-id pub-id-type="pmid">23436702</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0002">
<mixed-citation id="mgg3657-cit-0002" publication-type="journal">
<string-name>
<surname>Appignani</surname>, <given-names>B. A.</given-names>
</string-name>, <string-name>
<surname>Kaye</surname>, <given-names>E. M.</given-names>
</string-name>, &amp; <string-name>
<surname>Wolpert</surname>, <given-names>S. M.</given-names>
</string-name> (<year>1996</year>). <article-title>CT and MR appearance of the brain in two children with molybdenum cofactor deficiency</article-title>. <source xml:lang="en"/>American Journal of Neuroradiology, <volume>17</volume>(<issue>2</issue>), <fpage>317</fpage>–<lpage>320</lpage>. PMID: 8938304.<pub-id pub-id-type="pmid">8938304</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0003">
<mixed-citation id="mgg3657-cit-0003" publication-type="journal">
<string-name>
<surname>Arenas</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Fairbanks</surname>, <given-names>L. D.</given-names>
</string-name>, <string-name>
<surname>Vijayakumar</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Carr</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Escuredo</surname>, <given-names>E.</given-names>
</string-name>, &amp; <string-name>
<surname>Marinaki</surname>, <given-names>A. M.</given-names>
</string-name> (<year>2009</year>). <article-title>An unusual genetic variant in the <italic>MOCS1</italic> gene leads to complete missplicing of an alternatively spliced exon in a patient with molybdenum cofactor deficiency</article-title>. <source xml:lang="en"/>Journal of Inherited Metabolic Disease, <volume>32</volume>, <fpage>560</fpage>–<lpage>569</lpage>. <pub-id pub-id-type="doi">10.1007/s10545-009-1151-7</pub-id>
<pub-id pub-id-type="pmid">19544009</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0004">
<mixed-citation id="mgg3657-cit-0004" publication-type="journal">
<string-name>
<surname>Graf</surname>, <given-names>W. D.</given-names>
</string-name>, <string-name>
<surname>Oleinik</surname>, <given-names>O. E.</given-names>
</string-name>, <string-name>
<surname>Jack</surname>, <given-names>R. M.</given-names>
</string-name>, <string-name>
<surname>Weiss</surname>, <given-names>A. H.</given-names>
</string-name>, &amp; <string-name>
<surname>Johnson</surname>, <given-names>J. L.</given-names>
</string-name> (<year>1998</year>). <article-title>A homocysteinemia in molybdenum cofactor deficiency</article-title>. <source xml:lang="en"/>Neurology, <volume>51</volume>, <fpage>860</fpage>–<lpage>862</lpage>. PMID: 9748040. <pub-id pub-id-type="doi">10.1212/WNL.51.3.860</pub-id>
<pub-id pub-id-type="pmid">9748040</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0005">
<mixed-citation id="mgg3657-cit-0005" publication-type="journal">
<string-name>
<surname>Hughes</surname>, <given-names>E. F.</given-names>
</string-name>, <string-name>
<surname>Fairbanks</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Simmonds</surname>, <given-names>H. A.</given-names>
</string-name>, &amp; <string-name>
<surname>Robinson</surname>, <given-names>R. O.</given-names>
</string-name> (<year>1998</year>). <article-title>Molybdenum cofactor deficiency‐phenotypic variability in a family with a late‐onset variant</article-title>. <source xml:lang="en"/>Developmental Medicine &amp; Child Neurology, <volume>40</volume>, <fpage>57</fpage>–<lpage>61</lpage>. PMID: 9459218. <pub-id pub-id-type="doi">10.1111/j.1469-8749.1998.tb15357.x</pub-id>
<pub-id pub-id-type="pmid">9459218</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0006">
<mixed-citation id="mgg3657-cit-0006" publication-type="journal">
<string-name>
<surname>Huijmans</surname>, <given-names>J. G. M.</given-names>
</string-name>, <string-name>
<surname>Schot</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>de Klerk</surname>, <given-names>J. B.</given-names>
</string-name>, <string-name>
<surname>Williams</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>de Coo</surname>, <given-names>R. F. M.</given-names>
</string-name>, <string-name>
<surname>Duran</surname>, <given-names>M.</given-names>
</string-name>, … <string-name>
<surname>Mancini</surname>, <given-names>G. M. S.</given-names>
</string-name> (<year>2017</year>). <article-title>Molybdenum cofactor deficiency: Identification of a patient with homozygote mutation in the <italic>MOCS3</italic> gene</article-title>. <source xml:lang="en"/>American Journal of Medical Genetics Part A, <volume>173</volume>(<issue>6</issue>), <fpage>1601</fpage>–<lpage>1606</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.a.38240</pub-id>
<pub-id pub-id-type="pmid">28544736</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0007">
<mixed-citation id="mgg3657-cit-0007" publication-type="journal">
<string-name>
<surname>Johnson</surname>, <given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Coyne</surname>, <given-names>K. E.</given-names>
</string-name>, <string-name>
<surname>Rajagopalan</surname>, <given-names>K. V.</given-names>
</string-name>, <string-name>
<surname>Van Hove</surname>, <given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Mackay</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Pitt</surname>, <given-names>J.</given-names>
</string-name>, &amp; <string-name>
<surname>Boneh</surname>, <given-names>A.</given-names>
</string-name> (<year>2001</year>). <article-title>Molybdopterin synthase mutations in a mild case of molybdenum cofactor deficiency</article-title>. <source xml:lang="en"/>American Journal of Medical Genetics, <volume>104</volume>(<issue>2</issue>), <fpage>169</fpage>–<lpage>173</lpage>. <pub-id pub-id-type="doi">10.1002/1096-8628(20011122)104:2&lt;169:AID-AJMG1603&gt;3.0.CO;2-8</pub-id>
<pub-id pub-id-type="pmid">11746050</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0008">
<mixed-citation id="mgg3657-cit-0008" publication-type="journal">
<string-name>
<surname>Johnson</surname>, <given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Wuebbens</surname>, <given-names>M. M.</given-names>
</string-name>, <string-name>
<surname>Mandell</surname>, <given-names>R.</given-names>
</string-name>, &amp; <string-name>
<surname>Shih</surname>, <given-names>V. E.</given-names>
</string-name> (<year>1988</year>). <article-title>Molybdenum cofactor deficiency in a patient previously characterized as deficient in sulfite oxidase</article-title>. <source xml:lang="en"/>Biochemical Medicine and Metabolic Biology, <volume>40</volume>, <fpage>86</fpage>–<lpage>93</lpage>. <ext-link ext-link-type="uri" xlink:href="0.1016/0885-4505(88)90108-9">0.1016/0885-4505(88)90108-9</ext-link>
<pub-id pub-id-type="pmid">3219233</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0009">
<mixed-citation id="mgg3657-cit-0009" publication-type="journal">
<string-name>
<surname>Kumar</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Dejanovic</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Hetsch</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Semtner</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Fusca</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Arjune</surname>, <given-names>S.</given-names>
</string-name>, … <string-name>
<surname>Belaidi</surname>, <given-names>A. A.</given-names>
</string-name> (<year>2017</year>). <article-title>S‐sulfocysteine/NMDA receptor‐dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency</article-title>. <source xml:lang="en"/>Journal of Clinical Investigation, <volume>127</volume>(<issue>12</issue>), <fpage>4365</fpage>–<lpage>4378</lpage>. <pub-id pub-id-type="doi">10.1172/JCI89885</pub-id>
<pub-id pub-id-type="pmid">29106383</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0010">
<mixed-citation id="mgg3657-cit-0010" publication-type="journal">
<string-name>
<surname>Leimkuhler</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Freuer</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Araujo</surname>, <given-names>J. A.</given-names>
</string-name>, <string-name>
<surname>Rajagopalan</surname>, <given-names>K. V.</given-names>
</string-name>, &amp; <string-name>
<surname>Mendel</surname>, <given-names>R. R.</given-names>
</string-name> (<year>2003</year>). <article-title>Mechanistic studies of human molybdopterin synthase reaction and characterization of mutants identified in group B patients of molybdenum cofactor deficiency</article-title>. <source xml:lang="en"/>Journal of Biological Chemistry, <volume>278</volume>(<issue>28</issue>), <fpage>26127</fpage>–<lpage>26134</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M303092200</pub-id>
<pub-id pub-id-type="pmid">12732628</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0011">
<mixed-citation id="mgg3657-cit-0011" publication-type="journal">
<string-name>
<surname>Lubout</surname>, <given-names>C. M. A.</given-names>
</string-name>, <string-name>
<surname>Derks</surname>, <given-names>T. G. J.</given-names>
</string-name>, <string-name>
<surname>Meiners</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Erwich</surname>, <given-names>J. J.</given-names>
</string-name>, <string-name>
<surname>Bergman</surname>, <given-names>K. A.</given-names>
</string-name>, <string-name>
<surname>Lunsing</surname>, <given-names>R. J.</given-names>
</string-name>, … <string-name>
<surname>van Spronsen</surname>, <given-names>F. J.</given-names>
</string-name> (<year>2018</year>). <article-title>Molybdenum cofactor deficiency type A: Prenatal monitoring using MRI</article-title>. <source xml:lang="en"/>European Journal of Paediatric Neurology, <volume>22</volume>(<issue>3</issue>), <fpage>536</fpage>–<lpage>540</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpn.2017.11.006</pub-id>
<pub-id pub-id-type="pmid">29274890</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0012">
<mixed-citation id="mgg3657-cit-0012" publication-type="journal">
<string-name>
<surname>Mayr</surname>, <given-names>S. J.</given-names>
</string-name>, <string-name>
<surname>Sass</surname>, <given-names>J. O.</given-names>
</string-name>, <string-name>
<surname>Vry</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Kirschner</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Mader</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Hövener</surname>, <given-names>J. B.</given-names>
</string-name>, … <string-name>
<surname>Grünert</surname>, <given-names>S. C.</given-names>
</string-name> (<year>2018</year>). <article-title>A mild case of molybdenum cofactor deficiency defines an alternative route of <italic>MOCS1</italic> protein maturation</article-title>. <source xml:lang="en"/>Journal of Inherited Metabolic Disease, <volume>41</volume>, <fpage>187</fpage>–<lpage>196</lpage>. <pub-id pub-id-type="doi">10.1007/s10545-018-0138-7</pub-id>
<pub-id pub-id-type="pmid">29368224</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0013">
<mixed-citation id="mgg3657-cit-0013" publication-type="journal">
<string-name>
<surname>Mechler</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Mountford</surname>, <given-names>W. K.</given-names>
</string-name>, <string-name>
<surname>Hoffmann</surname>, <given-names>G. F.</given-names>
</string-name>, &amp; <string-name>
<surname>Ries</surname>, <given-names>M.</given-names>
</string-name> (<year>2015</year>). <article-title>Ultra‐orphan diseases: A quantitative analysis of the natural history of molybdenum cofactor deficiency</article-title>. <source xml:lang="en"/>Genetics in Medicine, <volume>17</volume>, <fpage>965</fpage>–<lpage>970</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2015.12</pub-id>
<pub-id pub-id-type="pmid">25764214</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0014">
<mixed-citation id="mgg3657-cit-0014" publication-type="journal">
<string-name>
<surname>Megahed</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Nicouleau</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Barcia</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Medina‐Cano</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Siquier‐Pernet</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Bole‐Feysot</surname>, <given-names>C.</given-names>
</string-name>, … <string-name>
<surname>Cantagrel</surname>, <given-names>V.</given-names>
</string-name> (<year>2016</year>). <article-title>Utility of whole exome sequencing for the early diagnosis of pediatric‐onset cerebellar atrophy associated with developmental delay in an inbred population</article-title>. <source xml:lang="en"/>Orphanet Journal of Rare Diseases, <volume>11</volume>, <fpage>57</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1186/s13023-016-0436-9</pub-id>
<pub-id pub-id-type="pmid">27146152</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0015">
<mixed-citation id="mgg3657-cit-0015" publication-type="journal">
<string-name>
<surname>Mize</surname>, <given-names>C. E.</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>, <given-names>J. L.</given-names>
</string-name>, &amp; <string-name>
<surname>Rajagopalan</surname>, <given-names>K. V.</given-names>
</string-name> (<year>1995</year>). <article-title>Defective molybdopterin biosynthesis: Clinical heterogeneity associated with molybdenum cofactor deficiency</article-title>. <source xml:lang="en"/>Journal of Inherited Metabolic Disease, <volume>18</volume>, <fpage>283</fpage>–<lpage>290</lpage>. <pub-id pub-id-type="doi">10.1007/BF00710416</pub-id>
<pub-id pub-id-type="pmid">7474893</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0016">
<mixed-citation id="mgg3657-cit-0016" publication-type="journal">
<string-name>
<surname>Parini</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Briscioli</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Caruso</surname>, <given-names>U.</given-names>
</string-name>, <string-name>
<surname>Dorche</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Fortuna</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Minniti</surname>, <given-names>G.</given-names>
</string-name>, … <string-name>
<surname>Mancini</surname>, <given-names>G.</given-names>
</string-name> (<year>1997</year>). <article-title>Spherophakia associated with molybdenum cofactor deficiency</article-title>. <source xml:lang="en"/>American Journal of Medical Genetics, <volume>73</volume>, <fpage>272</fpage>–<lpage>275</lpage>. <pub-id pub-id-type="doi">10.1002/humu.21390</pub-id>
<pub-id pub-id-type="pmid">9415683</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0017">
<mixed-citation id="mgg3657-cit-0017" publication-type="journal">
<string-name>
<surname>Reiss</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Gross‐Hardt</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Christensen</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Mendel</surname>, <given-names>R.</given-names>
</string-name>, &amp; <string-name>
<surname>Schwarz</surname>, <given-names>G.</given-names>
</string-name> (<year>2001</year>). <article-title>A mutation in the gene for the neurotransmitter receptor‐clustering protein gephyrin causes a novel form of molybdenum cofactor deficiency</article-title>. <source xml:lang="en"/>The American Journal of Human Genetics, <volume>68</volume>, <fpage>208</fpage>–<lpage>213</lpage>. <pub-id pub-id-type="doi">10.1086/316941</pub-id>
<pub-id pub-id-type="pmid">11095995</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0018">
<mixed-citation id="mgg3657-cit-0018" publication-type="journal">
<string-name>
<surname>Reiss</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lenz</surname>, <given-names>U.</given-names>
</string-name>, <string-name>
<surname>Aquaviva‐Bourdain</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Joriot‐Chekaf</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Mention‐Mulliez</surname>, <given-names>K.</given-names>
</string-name>, &amp; <string-name>
<surname>Holder‐Espinasse</surname>, <given-names>M.</given-names>
</string-name> (<year>2011</year>). <article-title>
<italic>GPHN</italic> point mutation leading to molybdenum cofactor deficiency</article-title>. <source xml:lang="en"/>Clinical Genetics, <volume>80</volume>, <fpage>598</fpage>–<lpage>599</lpage>. <pub-id pub-id-type="doi">10.1111/j.13990004.2011.01709</pub-id>
<pub-id pub-id-type="pmid">22040219</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0019">
<mixed-citation id="mgg3657-cit-0019" publication-type="journal">
<string-name>
<surname>Shih</surname>, <given-names>V. E.</given-names>
</string-name>, <string-name>
<surname>Abroms</surname>, <given-names>I. F.</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>, <given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Carney</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Mandell</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Robb</surname>, <given-names>R. M.</given-names>
</string-name>, … <string-name>
<surname>Rajagopalan</surname>, <given-names>K. V.</given-names>
</string-name> (<year>1977</year>). <article-title>Sulfte oxidase defciency. Biochemical and clinical investigations of a hereditary metabolic disorder in sulfur metabolism</article-title>. <source xml:lang="en"/>New England Journal of Medicine, <volume>297</volume>, <fpage>1022</fpage>–<lpage>1028</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM197711102971902</pub-id>
<pub-id pub-id-type="pmid">302914</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0020">
<mixed-citation id="mgg3657-cit-0020" publication-type="journal">
<string-name>
<surname>Vijayakumar</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Gunny</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Grunewald</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Carr</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Chong</surname>, <given-names>K. W.</given-names>
</string-name>, <string-name>
<surname>DeVile</surname>, <given-names>C.</given-names>
</string-name>, … <string-name>
<surname>Prabhakar</surname>, <given-names>P.</given-names>
</string-name> (<year>2011</year>). <article-title>Clinical neuroimaging features and outcome in molybdenum cofactor deficiency</article-title>. <source xml:lang="en"/>Pediatric Neurology, <volume>45</volume>, <fpage>246</fpage>–<lpage>252</lpage>. <pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2011.06.006</pub-id>
<pub-id pub-id-type="pmid">21907887</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0021">
<mixed-citation id="mgg3657-cit-0021" publication-type="journal">
<string-name>
<surname>Zaki</surname>, <given-names>M. S.</given-names>
</string-name>, <string-name>
<surname>Selim</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>El‐Bassyouni</surname>, <given-names>H. T.</given-names>
</string-name>, <string-name>
<surname>Issa</surname>, <given-names>M. Y.</given-names>
</string-name>, <string-name>
<surname>Mahmoud</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Ismail</surname>, <given-names>S.</given-names>
</string-name>, … <string-name>
<surname>Abdel Hamid</surname>, <given-names>M. S.</given-names>
</string-name> (<year>2016</year>). <article-title>Molybdenum cofactor and isolated sulphite oxidase deficiencies: Clinical and molecular spectrum among Egyptian patients</article-title>. <source xml:lang="en"/>European Journal of Paediatric Neurology, <volume>20</volume>(<issue>5</issue>), <fpage>714</fpage>–<lpage>722</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpn.2016.05.011</pub-id>
<pub-id pub-id-type="pmid">27289259</pub-id></mixed-citation>
</ref>
<ref id="mgg3657-bib-0022">
<mixed-citation id="mgg3657-cit-0022" publication-type="journal">
<string-name>
<surname>Zhang</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Vincent</surname>, <given-names>A. S.</given-names>
</string-name>, <string-name>
<surname>Halliwell</surname>, <given-names>B.</given-names>
</string-name>, &amp; <string-name>
<surname>Wong</surname>, <given-names>K. P.</given-names>
</string-name> (<year>2004</year>). <article-title>A mechanism of sulphite neurotoxicity: Direct inhibition of glutamate dehydrogenase</article-title>. <source xml:lang="en"/>Journal of Biological Chemistry, <volume>279</volume>(<issue>41</issue>), <fpage>43035</fpage>–<lpage>43045</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M402759200</pub-id>
<pub-id pub-id-type="pmid">15273247</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>